Celldex Therapeutics, of Phillipsburg, N.J., appointed Ronald Newbold vice president of business development, and Robert Forbes Burns CEO.

Cephalon Inc., of Frazer, Pa., appointed Kevin Moley to its board.

ChondroGene Ltd., of Toronto, appointed David Tyler director, product development and quality assurance.

ConjuChem Inc., of Montreal, appointed Thomas Ulich executive vice president, research and development.

Esbatech AG, of Zurich, Switzerland, appointed James Egan chief business officer.

Foley & Lardner LLP, of Boston, appointed Sven Riethmueller a member of its business law department and life sciences and emerging technologies industry teams.

Genentech Inc., of South San Francisco, appointed Michael Miller vice president, sales and marketing, HER family; and David Schenkein vice president, clinical hematology and oncology.

Genitope Corp., of Redwood City, Calif., appointed Mary Rybak vice president of medical affairs.

Genstruct Inc., of Cambridge, Mass., appointed Michelle Gordon-Savenor director of alliance management.

GlobeImmune Inc., of Louisville, Colo., appointed Jeffrey Rona chief business officer.

GTx Inc., of Memphis, Tenn., appointed Michael Carter to its board.

Ibex Technologies Inc., of Montreal, appointed Robert Heft director.

ImClone Systems Inc., of New York, appointed Alex Denner to its board.

Innovive Pharmaceuticals Inc., of New York, appointed Neil Herskowitz to its board.

Inyx Inc., of New York, appointed David Zinn vice president, finance; and William Kelly vice president, investor relations and corporate communications.

Labopharm Inc., of Laval, Quebec, appointed Santo Costa chairman.

LigoCyte Pharmaceuticals, of Bozeman, Mont., appointed Donald Beeman CEO.

Lipid Sciences Inc., of Pleasanton, Calif., appointed John Crawford to its board.

Merrimack Pharmaceuticals Inc., of Cambridge, Mass., appointed Sarah Nash and Steven Wheelwright to its board; and Fazal Khan vice president of manufacturing.

Migenix Inc., of Vancouver, British Columbia, appointed AnnKatrin Petersen vice president of clinical development.

Neurochem Inc., of Laval, Quebec, appointed Barry Greenberg senior director, pharmacology, and promoted David Skinner to vice president, general counsel and corporate secretary.

NitroMed Inc., of Lexington, Mass., appointed Christopher Sobecki to its board.

Novavax Inc., of Malvern, Pa., appointed Jinyou Zhang senior director of bioprocess R&D; and Niranjan Kumar senior director of commercial manufacturing.

Novo Nordisk, of Princeton, N.J., appointed Edward Williams vice president of biopharmaceuticals.

Novocell Inc., of Irvine, Calif., appointed Alan Lewis president and CEO.

NPS Pharmaceuticals, of Parsippany, N.J., appointed Tony Coles CEO.

Oncolytics Biotech Inc., of Calgary, Alberta, appointed Ed Levy to its board.

Othera Pharmaceuticals Inc., of Exton, Pa., appointed Katherine Crothall and Bruce Peacock to its board.

Panacos Pharmaceuticals Inc., of Watertown, Mass., appointed Frederick Schmid senior vice president, commercial operations and business development.

Pharmacopeia, of Princeton, N.J., promoted Brian Posner executive vice president and chief financial officer.

Pharmion Corp., of Boulder, Colo., appointed Andrew Allen chief medical officer.

Phenomix Corp., of San Diego, appointed David Gryska to its board.

Pieris Proteolab AG, of Freising-Weihenstephan, Germany, appointed Evert Kuppers CEO.

Proteon Therapeutics Inc., of Kansas City, Mo., appointed Timothy Noyes president and CEO.

Raven Biotechnologies Inc., of South San Francisco, appointed George Schreiner CEO and director.

Renovis Inc., of South San Francisco, appointed Donald Joseph senior vice president, corporate development and general counsel.

Resverlogix Corp., of Calgary, Alberta, appointed George Adams to its scientific advisory board.

Rhei Pharmaceuticals Inc., of New Haven, Conn., appointed Scott Kozak vice president of commercial operations.

Rosetta Genomics, of Rehovot, Israel, appointed Amir Avniel president and CEO.

Senetek plc, of Napa, Calif., appointed Rodger Bogardus and Kerry Dukes to its board.

Sequenom Inc., of San Diego, appointed Betty Dragon senior vice president of research and development.

Serono SA, of Geneva, appointed Jacques Theurillat senior executive vice president, strategic corporate development.

SkyePharma plc, of London, appointed Ken Cunningham director.

Somaxon Pharmaceuticals Inc., of San Diego, appointed Matthew Onaitis vice president of legal affairs.

No Comments